 |
|
Failure of Immunosuppression With a Ten- to 14-Day Course of High-Dose Intravenous Cyclophosphamide to Alter the Progression of Amyotrophic Lateral Sclerosis
Robert H. Brown, Jr, MD, PhD;
Stephen L. Hauser, MD;
Hugh Harrington, MD;
Howard L. Weiner, MD
Arch Neurol. 1986;43(4):383-384.
Abstract
• Amyotrophic lateral sclerosis (ALS) is a progressive disorder of the nervous system for which there is no known treatment. Because recent studies have suggested that there may be abnormalities of the immune function in patients with ALS and since we have found a beneficial effect from a short course of intensive immunosuppression with cyclophosphamide in progressive multiple sclerosis, we treated six patients with ALS with a ten- to 14-day course of intensive immunosuppression in a pilot study. At 18 months following therapy, all patients showed a continued progression of the disease; four of the six patients died. We conclude that this form of immunosuppression does not alter the course of ALS.
Author Affiliations
From the Neuromuscular Research Unit, Massachusetts General Hospital (Dr Brown), the Center for Neurologic Diseases, Brigham and Women's Hospital (Drs Hauser, Harrington, and Weiner), and the Harvard Medical School (Drs Brown, Hauser, Harrington, and Weiner), Boston.
Footnotes
Accepted for publication Sept 8, 1985.
Reprint requests to Neuromuscular Research Unit, Warren 374, Massachusetts General Hospital, 32 Fruit St, Boston, MA 02114 (Dr Brown).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Weiner and Cohen
Mult Scler 2002;8:142-154.
ABSTRACT
Immunosuppressive Treatment of Motor Neuron Syndromes-Reply
Tan et al.
Arch Neurol 1995;52:230-231.
ABSTRACT
Effect of High-Dose Intravenous Immunoglobulin on Amyotrophic Lateral Sclerosis and Multifocal Motor Neuropathy
Dalakas et al.
Arch Neurol 1994;51:861-864.
ABSTRACT
Amyotrophic Lateral Sclerosis: Recent Advances in Pathogenesis and Therapeutic Trials
Mitsumoto et al.
Arch Neurol 1988;45:189-202.
ABSTRACT
|
